Why is Monopar Therapeutics stock up today? Resistance levels in focus

Traders Union
All News
Stocks
Monopar Therapeutics jumps 3.59% today

Highlights

MNPR/USD maintains bullish momentum as it trades well above short-term and long-term moving averages across all timeframes.
Short-term momentum indicators are overbought, with visible buyer dominance but growing risk of near-term consolidation or pullback.
Price is expected to consolidate between $116.687 and $130.573 over the next 2 to 3 days, with a 75% probability of further upside.

Overbought signals emerge amid bullish trend continuation

On the H1 timeframe, MNPR is trading above its MA-20 at $117.82 and MA-50 at $113.33, as well as well above the long-term MA-200 at $71.44. The Ichimoku Kijun at $114.73 acts as immediate support. MACD shows a bullish configuration, while ADX is neutral. Oscillators such as RSI, Stoch RSI, CCI, and Bull/Bear Power are all in overbought territory, signaling strong buyer dominance during the session. The Awesome Oscillator also aligns with this uptrend, yet several indicators highlight overextension and potential for a short-term pullback.

Sideways move favored as volatility shapes range outlook

In the next 2 to 3 trading days, MNPR is expected to consolidate within a price range of $116.687 to $130.573, reflecting the current level of intraday volatility. There is a 75% probability of further upside within this corridor, while a move lower has a 25% likelihood. The baseline scenario favors sideways price action between immediate support and resistance, but a break above resistance could prompt a test toward the upper boundary. If price breaks below support, a move to the lower end of the expected range may follow.

Viktoras Karapetjanc, expert at Traders Union, notes sustained bullish momentum driving Monopar Therapeutics (MNPR) higher with price well above major moving averages. He sees technical strength confirmed by strong buyer dominance, yet recognizes oscillators are overbought and a short-term pullback cannot be ruled out. With no significant news to sway sentiment, Karapetjanc expects consolidation in the $116.687 to $130.573 range. The analyst assigns a higher probability for continued upside within this corridor. "The current uptrend is powerful, and unless support breaks, I remain optimistic on further gains," he says.

Earlier, analysts noted that Monopar Therapeutics was sustaining robust bullish momentum while signaling potential for near-term consolidation. The latest technicals reinforce this outlook and highlight that traders should closely monitor for an upside breakout above $130.573, which could indicate a renewed advance beyond the current trading corridor.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.